ADHERENCE TO TREATMENT OF PATIENTS WITH CHRONIC PROSTATITIS WITH CHRONIC PELVIC PAIN SYNDROME ACCORDING TO THE DURATION OF THE DISEASE AND UPOINT CLASSIFICATION

Objective: to study the adherence of patients with chronic prostatitis with chronic pelvic pain syndrome (CP/CPPS) to treat- ment, considering the duration of the disease and the features of the clinical course according to the UPOINT classification.

Material and methods. The transverse randomized uncontrolled study was performed on 112 patients diagnosed with CP/CPPS, with mean age 38.4±3.6 years. The duration of the disease varied from 1 to 12 years. The diagnosis of CP/CPPS was established on the basis of clinical symptoms and laboratory findings. All patients were assessed by their adherence to treatment and underwent a phenotypic classification in six domains depending on the clinical manifestations of the disease using the UPOINT method.

Results and discussion. When analyzing the data obtained in patients with CP/CPPS, an inverse correlation (r=-0.61) of a decrease in adherence to treatment with an increase in the duration of the disease was established. The maximum adherence to treatment was observed in the year of manifestation of the disease and amounted to 71.4%, while with a history of more than nine years, it decreased to 47.6%. The adherence study, taking into account the phenotyping of patients according to the UPOINT classification, showed the highest adherence to treatment in patients with CP/CPPS with a predominance of symptoms associated with the prostate. In this group, adherence to drug therapy was 88.1%, medical support - 84.7% and lifestyle modification - 79.1%.

Conclusions: 1. Adherence to treatment in patients with CP/CPPS is inversely correlated with the duration of the disease (r =- 0.61) and decreases most significantly (by 22.5%) in the period from 3 to 5 years of being ill.

2. Within the framework of adherence to the treatment of patients with CP/CPPS in the first year of the disease, according to the patients, drug therapy is of the greatest importance - 80.1%, medical support is considered less important - 72.6%, and the minimum contribution to treatment, in their opinion, is made by lifestyle changes.

1. Vinogradov IV. Evaluation of the efficacy and tolerability of combination therapy for lower urinary tract symptoms in patients with chronic prostatitis and benign prostatic hyperplasia//Experemental & clinical urology. – 2021. – No.1. – P. 37–43. DOI: 10.29188/2222-8543-2021-14-1-37-42. (in Russian)

2. Kogan MI. prostatic secretion microbiota: a comparative analysis of the chronical prostatitis II and IIIA category/ Kogan MI., Naboka YL., Ismailov RS.// Urology.– 2020. – No. 2. – P. 16-22. (in Russian)

3. EAU Guidelines. Edn. presented at the EAU Annual Congress, Amsterdam, the Netherlands, 2020. ISBN 978-94-92671-07-3. (in English)

4. Khatri, G., et al. Diagnostic Evaluation of Chronic Pelvic Pain. Phys Med Rehabil Clin N Am, 2017. 28: 477. https://www.ncbi.nlm.nih.gov/pubmed/28676360

5. Sivkov AV., Romikh VV., Zakharchenko AV./Chronic prostatitis IIIB/chronic pelvic pain syndrome and sexual dysfunction Andrology and genital surgery. //2015. Vol. 16. №. 4. P. 18-26. (in English)

6. Magistro G., Wagenlehner FM., Grabe M. [et al.] Contemporary management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol 2016;69(2):286–97 (in English)

7. Magri V, Boltri M, Cai T, [et al.]/Multidisciplinary approach to prostatitis// Arch Ital Urol Androl. 2019 Jan 18;90(4):227-248. doi: 10.4081/aiua.2018.4.227. (in English)

8. Krakhotkin DV, Chernylovskyi VA, Bakurov EE, [et al.]/Evaluation of influence of the UPOINT-guided multimodal therapy in men with chronic prostatitis/chronic pelvic pain syndrome on dynamic values NIH-CPSI: a prospective, controlled, comparative study.//Ther Adv Urol. 2019 Jun 26;11:1756287219857271. doi: 10.1177/1756287219857271. eCollection 2019 Jan-Dec.PMID: 31263510. (in English)

9. Bryk DJ, Shoskes DA./Using the UPOINT system to manage men with chronic pelvic pain syndrome.//Arab J Urol. 2021 Jul 23;19(3):387-393. doi: 10.1080/2090598X.2021.1955546. eCollection 2021.PMID: 34552790. (in English)

10. Glushanko VS., Gaifullina RI. Assessment of treatment adherence: basic approaches. In the collection: Achievements of fundamental, clinical medicine and pharmacy. Materials of the 75th scientific session of the university staff. Vitebsk, 2020. pp. 582-584. (in Russian)

11. Kholkina AA., Isakov VA. The low patients adherence to medication as the problem of the modern healthcare. Diary of the Kazan medical school. 2019. No. 3 (25). pp. 38-43. (in Russian)

12. Nikolaev NA, Skirdenko YP. Russian universal questionnaire for quantitative assessment of adherence to treatment. Clinical pharmacology and therapy. 2018. Vol. 27. No. 1. pp. 74-78. (in Russian)

13. Popkov VM, Loyko VS, Mikhailov IV. Evaluation of the development time and characteristics of the clinical manifestations of chronic prostatitis/chronic pelvic pain syndrome in men, taking into account the age and body weight according to UPOINT classification/ Saratov Scientific Medical Journal. 2020. Vol. 16. №. 1. P. 69-72. (in Russian)

14. Doiron RC, Tripp DA, Tolls V, [et al.] /The evolving clinical picture of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): A look at 1310 patients over 16 years.// Can Urol Assoc J. 2018 Jun;12(6):196-202. doi: 10.5489/cuaj.4876. Epub 2018 Feb 23.PMID: 29485036. (in English)